This included assessments of proteins of interest that drive PI3K pathway signaling such as phosphorylated protein kinase B (pAKT) and phosphatase and tensin homolog (PTEN), evaluation of the immune composition of the tumor microenvironment via specific markers for regulatory T cells [Treg; cluster of differentiation (CD) 4 and forkhead box protein 3 (FoxP3)], infiltrating antitumor CD8 T cells (Ki-67 and CD8), and regulatory tumor-associated macrophages (TAMs; CD68 and PD-L1), and global flow cytometry analyses of immune cell subset populations before and after treatment. This evidence concerns the gene MKI67 and neoplasm.